Get the Stockscreener App
361.61
0.22%
1.055
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $361.61, with a volume of 882.82K.
It is up +0.22% in the last 24 hours and up +7.29% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$360.55
Open:
$362.15
24h Volume:
882.82K
Relative Volume:
0.33
Market Cap:
$195.16B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
25.15
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+4.13%
1M Performance:
+7.29%
6M Performance:
+9.93%
1Y Performance:
+29.42%
1-Day Range:
$356.87
$362.50
1-Week Range:
$346.00
$363.11
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
361.60 | 193.39B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,210.97 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.51 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
252.06 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.95 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.84 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Faces Fresh Pressure After NEJM Retracts Trial Behind $459 Million Drug - GuruFocus
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Pathway Financial Advisers LLC Sells 5,382 Shares of Amgen Inc. $AMGN - MarketBeat
Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now. - The Motley Fool
Forum Financial Management LP Sells 2,792 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Weighs Strong Run Against Mixed Valuation Signals - Yahoo Finance
Heart and Kidney Medications Recalled Nationwide—Over 900,000 Bottles Affected - EatingWell
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings - Reuters
Amgen (AMGN) Faces Setback as Clinical Trial Article Retracted - GuruFocus
Amgen Drug Tavneos’ Main Study Retracted by Medical Journal - Bloomberg.com
Recall alert: Nearly 1M bottles of kidney, heart medications recalled - WHIO TV
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Benzinga
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Bases as Healthcare Ramps for NASDAQ:AMGN by TradeStation - TradingView
Matrix Asset Advisors Inc. NY Sells 3,739 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen advances obesity pipeline focus, shares hold near recent highs - AD HOC NEWS
Amgen Inc. $AMGN Holdings Lifted by Fort Washington Investment Advisors Inc. OH - MarketBeat
Amgen sets late-stage obesity data milestone, shares on watch for Wegovy and Zepbound competition - AD HOC NEWS
BLINCYTO from Amgen Inc.immunotherapy that reshapes leukemia care - Ad-hoc-news.de
FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med - MedCity News
Amgen Recalls Corlanor and Sensipar Tablets Over Foreign Substance RiskNews and Statistics - IndexBox
Amgen Sunday strategy focus, stock and pipeline under long-term scrutiny - Ad-hoc-news.de
Janney Montgomery Scott LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Nicholas Wealth LLC. Takes $1.16 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets - Fox Business
Price to book forward of Amgen Inc. – NASDAQ:AMGN - TradingView
The Evenity from Amgen Inc.osteoporosis therapy with a defined 12-month window - Ad-hoc-news.de
Amgen updates phase 2 obesity data, shares closely watched by health investors - Ad-hoc-news.de
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles - People.com
Nearly 1 million bottles of medication used to treat heart failure recalled nationwide - PIX11
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors - Kavout | AI
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh - TradingView
Amgen Continues To Perform (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Amgen Inc. – MUN:AMG - TradingView
Enterprise value to EBIT forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen consensus steady ahead of next earnings, shares tracked against big pharma peers - Ad-hoc-news.de
Enterprise value to EBIT forward of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGDB - TradingView
Amgen Inc. Actuals & Estimates (NASDAQ:AMGN) - TradingView
EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked - WSJ
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - marketscreener.com
EMA recommends revoking marketing authorisation for Amgen’s rare-disease drug - WKZO
Amgen faces EU withdrawal of rare-disorder therapy Tavneos - Seeking Alpha
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Amgen highlights obesity pipeline progress, shares track pharma peers - Ad-hoc-news.de
Meyer Handelman Co. Trims Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Actuals & Estimates (BX:AMG) - TradingView
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):